UnknownPhase 4

Sacubitril/Valsartan Versus Amlodipine in Hypertension and Left Ventricular Hypertrophy.

China120 participantsStarted 2021-11-28

Plain-language summary

1. Study name: Prospective Comparison of Angiotensin receptor neprilysin inhibitor (ARNI) with Amlodipine on ventricular remodeling in hypertension and left ventricular hypertrophy. 2. Medicine: sacubitril/valsartan (ARNI, 200mg tablet) and the matching placebo; amlodipine (5mg tablet) and the matching placebo. 3. Rationale: according to the results of previous clinical studies, ARNI has obvious advantages in improving cardiac remodeling and reducing blood pressure. However, there is no evidence to demonstrate the efficacy of ARNI in reducing blood pressure and improving ventricular remodeling in hypertension patients with left ventricular hypertrophy (LVH) compared with calcium channel blockers. 4. Objective: to demonstrate the superior efficacy of ARNI on improvement of LVH and blood pressure control compared with amlodipine in hypertension patients with LVH. 5. Study design: This study This is a 24-week prospective, randomized, active-controlled, double-blind, multi-center study, with two equally sized treatment groups: sacubitril/valsartan (200mg tablet); amlodipine (5mg tablet). 6. Study population: men or women aged over 18 years; Untreated patients or patients with taking single antihypertensive drugs; Essential mild to moderate hypertension; Echocardiographic diagnosis of LVH. 7. Randomization and treatment: Eligible patients will be randomly divided into 2 groups, taking one pill of sacubitril/valsartan (200mg tablet) + one pill of matching placebo of amlodipine daily, or one pill of amlodipine (5 mg/tablet) + one pill of matching placebo of sacubitril/valsartan daily. 8. Follow up: after meeting the inclusion criteria, there will be 2-week placebo run-in. Then patients will be randomly assigned into ARNI group and amlodipine group. There will be 5 visiting points in the treatment period, which will be the 4th week, 8th week, 12th week, 18th week and 24th week. 9. Sample size: 120 patients in total. 10. Timeline: After obtaining the approval of Ethics Committee of Ruijin Hospital in April 2021, recruitment will start. Patients enrollment and follow-up will be performed between June 2021 to June 2022.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged ≥18; * Essential mild to moderate hypertension (office systolic blood pressure (SBP) ≥ 140 and \< 180mmHg in untreated patients or patients with taking single antihypertensive drugs (not including single-pill combination))； * Echocardiographic diagnosis of LVH，LVMI: male≥115g/m2, female≥ 95g/m2; * Ability to understand the study requirements and provide informed consent. Exclusion Criteria: * Hypersensitivity history to any study drug or similar drug (ARB, ACEI, neprilysin inhibitor； * Severe renal insufficiency (eGFR \< 30 mL/min/1.73m2); * Hyperkalemia (serum potassium \> 5mmol/L); * Active liver disease or hepatic insufficiency (AST or ALT \> 3 times upper limit of normal); * History of malignancy over the past 5 years; * Severe disease patients with life expectancy of \< 1 year; * Previous or current diagnosis of heart failure; * Stroke or myocardial infarction within 6 months; * Previous or current atrial fibrillation, frequent ventricular premature beats, supraventricular tachycardia; * Patients who are receiving other study drugs or study medical devices; * Pregnant or lactating women; * Other circumstances that patients are not appropriate for the study upon the investigator's judgment.

What they're measuring

Change in LVGLS after 24 weeks

Timeframe: Baseline and 24 weeks

Trial details

NCT IDNCT04929600

SponsorShanghai Jiao Tong University School of Medicine

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-06